Sanofi
Last updated Jul 28, 2026
Evidence Sources
5
Competitive Findings
0
Portfolio Developments
1
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 1
- Self-competition findings removed: 1
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Diabetes
- Insulin
- Cardiovascular
- Antihypertensive
- Cardiology
Highest priority development: FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)
Portfolio development
FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC) is an owned Sanofi portfolio development in Oncology · Monoclonal Antibody.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 69%
Active Signals
16
Investigate Priority
0
Opportunity Score
1409
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 28, 2026Score 92FDA grants supplemental application approval for Dupixent (BLA761055)
Immunology · IL-4/IL-13
- MonitorJun 25, 2026Score 90Sanofi's Venglustat Phase 3 Trial Targets Left Ventricular Mass in Fabry Disease
Cardiology · Fabry Disease
- MonitorJul 29, 2026Score 88FDA Accepts Supplemental NDA for AVAPRO by Sanofi
Cardiology · Antihypertensive
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsFDAPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/SubmissionsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Sanofi right now?
- Which regulatory precedents should Sanofi monitor in Diabetes and Insulin?
- Which pipeline programs should Sanofi prioritize for competitive review?
- What signals require immediate investigation for Sanofi?
- Summarize the strategic implications of recent developments for Sanofi.
- Where is the greatest uncertainty in Sanofi's competitive positioning?